Dan Shochat
Geen lopende functies
Profiel
Dan Shochat worked as a Principal at Wyeth Holdings LLC and Coulter Pharmaceuticals, Inc. where he held the position of Principal from 1995 to 2012.
He was also a Vice President at Deltagen, Inc., Humanigen, Inc., and Intellect Neurosciences, Inc. Additionally, he served as the Chief Technical Officer & Executive Vice President at Celscia Therapeutics, Inc. Dr. Shochat earned his doctorate degree from Louisiana State University in 1976.
He also received his undergraduate and graduate degrees from The Hebrew University of Jerusalem in 1965 and 1968, respectively.
Eerdere bekende functies van Dan Shochat
| Bedrijven | Functie | Einde |
|---|---|---|
| DELTAGEN INC. | Corporate Officer/Principal | 01-01-2002 |
| INTELLECT NEUROSCIENCES, INC. | Corporate Officer/Principal | - |
Celscia Therapeutics, Inc.
 Celscia Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Celscia Therapeutics, Inc. is a company that researches and develops antibody therapeutics for the treatment of cancer and inflammatory/autoimmune diseases. The company is based in South San Francisco, CA. The company was founded by Geoffrey Thomas Yarranton, Christopher Bebbington. Celscia Therapeutics was acquired by Humanigen, Inc. on January 12, 2004. | Hoofd Techniek/Wetenschap/O&O | - |
| HUMANIGEN, INC. | Corporate Officer/Principal | - |
Coulter Pharmaceuticals, Inc.
 Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Dan Shochat
| Louisiana State University | Doctorate Degree |
| The Hebrew University of Jerusalem | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| DELTAGEN INC. | Commercial Services |
| HUMANIGEN, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Wyeth Holdings LLC
 Wyeth Holdings LLC Chemicals: AgriculturalProcess Industries Wyeth Holdings LLC manufactures and distributes chemicals. The firm's chemical contains phosphate rock, calcium, lime, carbide and nitrogen which are used in fertilizers. The company was founded by Frank Washburn in 1907 and is headquartered in Wayne, NJ. | Process Industries |
Coulter Pharmaceuticals, Inc.
Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Health Technology |
Intellect Neurosciences, Inc.
 Intellect Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Intellect Neurosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of disease-modifying therapeutic agents. It specializes in treatment and prevention of neurodegenerative conditions, collectively known as proteinopathies, which include alzheimer's, parkinson's and huntington disease. The company was founded by Daniel G. Chain on April 25, 2005 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
Celscia Therapeutics, Inc.
Celscia Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Celscia Therapeutics, Inc. is a company that researches and develops antibody therapeutics for the treatment of cancer and inflammatory/autoimmune diseases. The company is based in South San Francisco, CA. The company was founded by Geoffrey Thomas Yarranton, Christopher Bebbington. Celscia Therapeutics was acquired by Humanigen, Inc. on January 12, 2004. | Commercial Services |
